Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN2D | O15399 | 1/20 | 0.53 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.53 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.53 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.53 |
| ▸ | GRIA3 | P42263 | 1/20 | 0.53 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.53 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.53 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.53 |
| ▸ | GRIK2 | Q13002 | 1/20 | 0.53 |
| ▸ | GRIK3 | Q13003 | 1/20 | 0.53 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.53 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.53 |
| ▸ | GRIK4 | Q16099 | 1/20 | 0.53 |
| ▸ | GRIK5 | Q16478 | 1/20 | 0.53 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.53 |
| ▸ | MMP1 | P03956 | 1/20 | 0.42 |
| ▸ | MMP2 | P08253 | 1/20 | 0.42 |
| ▸ | MMP3 | P08254 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3696226 | 0.82 | PIM1 (0.56) | ALDH1A1MAPTSMN1; SMN2MEN1KMT2A | |
| SCHEMBL3699368 | 0.80 | ALDH1A1 (0.42) | GRIN2DGRIN3BLMNAGRIK1GRIA1 | |
| SCHEMBL2548424 | 0.78 | MMP1 (0.42) | GRIN2DGRIN3BLMNAGRIK1GRIA1 | |
| 2,3-Dihydroxy-6,7-Dichloroquinoxaline SCHEMBL1259521 | 0.78 | MMP1 (0.50) | MMP1MMP2MMP3ALDH1A1GLP1R | |
| SCHEMBL6108802 | 0.76 | ALDH1A1 (0.44) | GRIN2DGRIN3BLMNAGRIK1GRIA1 | |
| SCHEMBL9703856 | 0.76 | GRIN2D (0.49) | GRIN2DGRIN3BLMNAGRIK1GRIA1 | |
| SCHEMBL11278799 | 0.75 | MMP1 (0.40) | GRIN2DGRIN3BLMNAGRIK1GRIA1 | |
| SCHEMBL42617 | 0.75 | ALDH1A1 (0.75) | ALDH1A1MAPTSMN1; SMN2MEN1KMT2A | |
| SCHEMBL2775275 | 0.74 | KDM4E (0.53) | ALDH1A1MAPTSMN1; SMN2KMT2APIM1 | |
| SCHEMBL26617913 | 0.74 | KDM4E (0.53) | ALDH1A1MAPTSMN1; SMN2KMT2APIM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180042899-A1 | Method of Treating Transplant Rejection and Autoimmune Diseases | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2018-02-15 | — | — | US | disclosed |
| US-20140050694-A1 | Method of Treating Transplant Rejection and Autoimmune Diseases | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2014-02-20 | — | — | US | disclosed |
| US-20090143279-A1 | Methods and compositions for treating metabolic disorders | PRESIDENT AND FELLOWS OF HARVARD COLLEGE | 2009-06-04 | — | — | US | disclosed |
| WO-2008156654-A2 | CYTOSKELETON MODULATORS FOR TREATING METABOLIC DISORDERS | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2008-12-24 | — | — | WO | disclosed |
| EP-0986758-B1 | DETECTION OF BIOLOGICALLY ACTIVE MOLECULES BY USE OF PRE-ACTIVATED CELL-BASED BIOSENSORS IN LIQUID-BASED SEPARATION SYSTEMS | CELLECTRICON AB (SE) | 2005-11-16 | — | — | EP | disclosed |
| US-20020182642-A1 | Biosensors and methods of using the same | CELLECTRICON AB (SE) | 2002-12-05 | — | — | US | disclosed |
| US-6455303-B1 | Detection of biologically active molecules by use of pre-activated cell-based biosensors in liquid-based separation systems | CELLECTRICON AB (SE) | 2002-09-24 | — | — | US | disclosed |
| EP-0986758-A1 | DETECTION OF BIOLOGICALLY ACTIVE MOLECULES BY USE OF PRE-ACTIVATED CELL-BASED BIOSENSORS IN LIQUID-BASED SEPARATION SYSTEMS | A+ Science Invest AB (SE) | 2000-03-22 | — | — | EP | disclosed |
| WO-1998055870-A1 | DETECTION OF BIOLOGICALLY ACTIVE MOLECULES BY USE OF PRE-ACTIVATED CELL-BASED BIOSENSORS IN LIQUID-BASED SEPARATION SYSTEMS | A+ SCIENCE INVEST AB (SE) | 1998-12-10 | — | — | WO | disclosed |
| EP-0682657-B1 | 9H-INDENO[1,2-b]PYRAZINE-3(4H)-ONES AND 9H-INDENO[1,2-b]PYRAZINE-2,3(1H,4H)-DIONES AND THEIR PREPARATION AND USE | NOVO NORDISK AS (DK) | 1997-11-19 | — | — | EP | disclosed |
| WO-1993008197-A1 | THIENOPYRAZINE-2,3-DIONES AND THEIR PREPARATION AND USE | NOVO NORDISK A/S (DK) | 1993-04-29 | — | — | WO | disclosed |
| EP-0526588-A1 | HETEROCYCLIC COMPOUNDS AND THEIR PREPARATION AND USE. | NOVO NORDISK AS (DK) | 1993-02-10 | — | — | EP | disclosed |
| US-5182279-A | Antiepileptic, anticonvulsant, anxiolytic, antiischemic | NOVO NORDISK A/S (DK) | 1993-01-26 | — | — | US | disclosed |
| EP-0520024-A1 | QUINOXALINE COMPOUNDS AND THEIR PREPARATION AND USE. | NOVO NORDISK AS (DK) | 1992-12-30 | — | — | EP | disclosed |
| US-5166155-A | Neurological or psychiatric diseases | NOVO NORDISK A/S (DK) | 1992-11-24 | — | — | US | disclosed |
| WO-1991016325-A1 | HETEROCYCLIC COMPOUNDS AND THEIR PREPARATION AND USE | NOVO NORDISK A/S (DK) | 1991-10-31 | — | — | WO | disclosed |
| WO-1991013878-A1 | QUINOXALINE COMPOUNDS AND THEIR PREPARATION AND USE | NOVO NORDISK A/S (DK) | 1991-09-19 | — | — | WO | disclosed |
| US-4264600-A | VIRICIDES | ELI LILLY AND COMPANY (US) | 1981-04-28 | — | — | US | disclosed |
| US-4252954-A | VIRICIDES | ELI LILLY AND COMPANY (US) | 1981-02-24 | — | — | US | disclosed |
| EP-0010426-A1 | Pharmaceutical composition containing 3,4-dihydro-3-oxo-2-quinoxalines, novel such quinoxalines and processes for the production thereof | ELI LILLY AND COMPANY (US) | 1980-04-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090143279-A1 | Methods and compositions for treating metabolic disorders | PC, PCK2, CS | GRIN2D 1031/4885GRIN3B 1154/4885LMNA 1929/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.